2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1017

Statistical Simulation Using Data from the Foundation for the National Institute of Health/Osteoarthritis Initiative Biomarkers Consortium to Evaluate the Clinical Utility of Prognostic Knee Osteoarthritis Biomarkers in Designing a Knee Osteoarthritis Clinical Trial
Abstract Number: 1018

Dietary Intake of Fiber and Risk of Knee Osteoarthritis
Abstract Number: 1019

The Impact of Hip and Knee Osteoarthritis on the Subsequent Risk of Incident Diabetes: A Population-Based Cohort Study
Abstract Number: 1020

Risk Factors Can Classify Individuals Who Develop Accelerated Knee Osteoarthritis
Abstract Number: 1021

Maintaining Sufficient Serum Vitamin D Levels over 2 Years Is Associated with Reduced Knee Structural and Symptomatic Changes in Patients with Knee Osteoarthritis
Abstract Number: 1022

The Risk of Symptomatic Knee Osteoarthritis after Arthroscopic Meniscus Repair Vs Partial Meniscectomy Vs the General Population
Abstract Number: 1023

Fracture Risk Reduction with Romosozumab: Results of a Phase 3 Study in Postmenopausal Women with Osteoporosis
Abstract Number: 1024

Superior Gains in Bone Mineral Density and Estimated Strength at the Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of a Phase 3, Open-Label Clinical Trial
Abstract Number: 1025

Assessment of the Effects of Switching Bisphosphonates to Denosumab or Daily Teriparatide in Patients with Rheumatoid Arthritis
Abstract Number: 1026

Morphea-like Skin Lesions Reported in the Phase 3 Long-Term Odanacatib Fracture Trial and Extension in Postmenopausal Women with Osteoporosis
Abstract Number: 1027

Odanacatib Efficacy and Safety in Postmenopausal Women with Osteoporosis: 5-Year Data from the Extension of the Phase 3 Long-Term Odanacatib Fracture Trial
Abstract Number: 1028

Discontinuation of Denosumab and Associated Vertebral Fracture Incidence: Analysis from a Phase 3 Placebo-Controlled Study of Denosumab and Its Open-Label Extension
Abstract Number: 1029

Functional Genetics of PTPN2 in Rheumatoid Arthritis: Haploinsufficiency of PTPN2 Promotes Severity of Th17-Cell Mediated Autoimmune Arthritis
Abstract Number: 1030

Synovial Tissue Resident Macrophages Play the Protective Role in the Development of Inflammatory Arthritis in CD11c-Flip-KO Mice
Abstract Number: 1031

Glucocorticoid Receptor Dimerization in Stromal Cells Modulates Macrophage Polarization during Serum Transfer-Induced Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].